This news is based on a press release statement from Structure Therapeutics. The company has cautioned that the results from preclinical studies may not be predictive of future clinical outcomes and that there are risks and uncertainties involved in the development and regulatory approval process. Structure Therapeutics has made no assurances that ACCG-2671 will ultimately be commercialized or achieve the anticipated safety, efficacy, or market acceptance. For comprehensive analysis of Structure Therapeutics' financial health and market position, investors can access detailed Pro Research Reports and additional insights through InvestingPro, which currently rates the company's overall financial health as "FAIR" with particular strength in cash flow metrics. For comprehensive analysis of Structure Therapeutics' financial health and market position, investors can access detailed Pro Research Reports and additional insights through InvestingPro, which currently rates the company's overall financial health as "FAIR" with particular strength in cash flow metrics.
ACCG-2671, a Dual Amylin and Calcitonin Receptor Agonist (DACRA), has shown promising results in preclinical studies, exhibiting potent target engagement, significant weight loss, and a safety profile that supports once-daily dosing in humans. The company’s research indicates that ACCG-2671 could offer a differentiated oral treatment option for obesity, with advantages including reduced food intake and a slower rate of gastric emptying.
This news is based on a press release statement from Structure Therapeutics. The company has cautioned that the results from preclinical studies may not be predictive of future clinical outcomes and that there are risks and uncertainties involved in the development and regulatory approval process. Structure Therapeutics has made no assurances that ACCG-2671 will ultimately be commercialized or achieve the anticipated safety, efficacy, or market acceptance. For comprehensive analysis of Structure Therapeutics' financial health and market position, investors can access detailed Pro Research Reports and additional insights through InvestingPro, which currently rates the company's overall financial health as "FAIR" with particular strength in cash flow metrics.
Dr. Xichen Lin, Chief Scientific Officer, highlighted the company's rapid advancement of ACCG-2671 using its GPCR structure-based drug discovery platform. Structure Therapeutics is also developing a series of amylin-based drug candidates to maintain its position in this therapeutic area.
Structure Therapeutics will host a conference call today to discuss the development of ACCG-2671 further. The company's portfolio includes several wholly-owned proprietary clinical-stage small molecule compounds, with ACCG-2671 being the first disclosed oral small molecule amylin-based development candidate.
This news is based on a press release statement from Structure Therapeutics. The company has cautioned that the results from preclinical studies may not be predictive of future clinical outcomes and that there are risks and uncertainties involved in the development and regulatory approval process. Structure Therapeutics has made no assurances that ACCG-2671 will ultimately be commercialized or achieve the anticipated safety, efficacy, or market acceptance.
In other recent news, Structure Therapeutics has been making significant strides in its strategic initiatives, particularly in the obesity treatment sector. The company has been preparing for the Phase 2b obesity trial of its lead pipeline asset, GSBR-1290, an oral GLP-1R agonist, slated to begin in late 2024. BMO Capital Markets and Morgan Stanley (NYSE:MS) have both maintained a positive outlook on the company, with BMO reiterating an Outperform rating and a price target of $100.00, and Morgan Stanley issuing an Overweight rating.
Structure Therapeutics has also been a focus of positive analyst attention from Piper Sandler, which has maintained its Overweight rating, noting the promising results from the GSBR-1290 program. The company has also seen significant changes in its leadership team, with Blai Coll promoted to Chief Medical (TASE:PMCN) Officer and Ashley Hall appointed as Chief Development Officer.
In anticipation of the upcoming trials, Structure Therapeutics has announced plans for an underwritten public offering of 8 million American Depositary Shares, with Goldman Sachs & Co. LLC, Morgan Stanley, Jefferies, Leerink Partners, Guggenheim Securities, and BMO Capital Markets as joint book-running managers. These are the recent developments for Structure Therapeutics as it continues to advance in its mission to develop oral treatments for metabolic and cardiopulmonary diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.